Who Exports Tamoxifen from India — 220 Suppliers Behind a $14.7M Market
India's tamoxifen export market is supplied by 220 active exporters who collectively shipped $14.7M across 3,139 shipments. EUGIA PHARMA SPECIALITIES LIMITED leads with a 45.3% market share, followed by PRATAP ORGANICS PRIVATE LIMITED and GRANULES INDIA LIMITED. The top 5 suppliers together control 87.8% of total export value, reflecting a concentrated market structure.
Top Tamoxifen Exporters from India — Ranked by Export Value
EUGIA PHARMA SPECIALITIES LIMITED is the leading tamoxifen exporter from India, holding a 45.3% share of the $14.7M market across 3,139 shipments from 220 exporters. The top 5 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, PRATAP ORGANICS PRIVATE LIMITED, GRANULES INDIA LIMITED, BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED, KHANDELWAL LABORATORIES PRIVATE LIMITED — collectively control 87.8% of total export value, indicating a highly concentrated market. Individual shares are: EUGIA PHARMA SPECIALITIES LIMITED (45.3%), PRATAP ORGANICS PRIVATE LIMITED (19.1%), GRANULES INDIA LIMITED (12.7%), BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED (5.6%), KHANDELWAL LABORATORIES PRIVATE LIMITED (5.0%).
Top Tamoxifen Exporters from India
Ranked by export value · 220 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | EUGIA PHARMA SPECIALITIES LIMITED TAMOXIFEN TABLET 20MGTAMOXIFEN TABLETS BP 20MGTAMOXIFEN 20 MG TABLETS 3X10 S | $6.7M | 5 | 45.3% |
| 2 | PRATAP ORGANICS PRIVATE LIMITED TAMOXIFEN BASE KGSTAMOXIFEN BASE CAS NO. 10540-29-1TAMOXIFEN BASE CASE NO 10540 29 1 | $2.8M | 1 | 19.1% |
| 3 | GRANULES INDIA LIMITED TAMOXIFEN BASE KGSTAMOXIFEN BASE CAS NO. 10540-29-1TAMOXIFEN AL 20 10X10 S ST ADA AL | $1.9M | 2 | 12.7% |
| 4 | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED MAMOFEN 20 (PHARMACTAMOXIFEN TABLETS BP 20MGTAMOXIFEN 20 MG TABLETS 3X10 S | $830.4K | 2 | 5.6% |
| 5 | KHANDELWAL LABORATORIES PRIVATE LIMITED MAMOFEN 20 (PHARMACMAMOFEN 20TAMOXIFEN CITRATE TABLETS USP 20MG 10X10 | $742.7K | 7 | 5.0% |
| 6 | WOCKHARDT LIMITED TAMOXIFEN TABLETS BP 20MGTAMOXIFEN 20 MG TABLETS 3X10 STAMOXIFEN 20 MG TABLETS | $409.8K | 1 | 2.8% |
| 7 | STERIL-GENE LIFE SCIENCES PRIVATE LIMITED TAMOXIFEN TABLETS BP 20MGTAMOXIFEN 20 MG TABLETS 3X10 STAMOXIFEN 20 MG TABLETS | $254.0K | 1 | 1.7% |
| 8 | STERIL GENE LIFE SCIENCES PRIVATE LIMITED TAMOXIFEN TABLETS BP 20MGTAMOXIFEN 20 MG TABLETS 3X10 STAMOXIFEN 20 MG TABLETS | $162.3K | 1 | 1.1% |
| 9 | MEDWISE OVERSEAS PRIVATE LIMITED TAMOXIFEN TABLETSTAMOXIMED-20 (TAMOXIFEN CITRATE TABLETSNOLVABOLIC,TAMOXIFEN CITRATE 20MG. ,B | $85.0K | 3 | 0.6% |
| 10 | KWALITY PHARMACEUTICALS LIMITED TAMOXIFEN TABLETSTAMOXIFEN CITRATE TABLETS USP 10 MG | $73.7K | 1 | 0.5% |
| 11 | FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED | $50.5K | 1 | 0.3% |
| 12 | BAFNA PHARMACEUTICALS LIMITED TAMOXIFEN CITRATE TABLETS USP 20MG 10X10553050 TABLETS OF TAMOXIFEN TABLETS BP 2TAMCOR-20 | $48.3K | 1 | 0.3% |
| 13 | NEON LABORATORIES LIMITED | $42.0K | 3 | 0.3% |
| 14 | CAPLIN POINT LABORATORIES LIMITED | $41.1K | 3 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Tamoxifen exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Eugia Pharma Specialities Limited | Warning Letter, August 20 | Yes, as of December | No | Not verified | Received FDA Warning Letter in August 2024 for CGMP violations at Unit III facil |
| BDR Pharmaceuticals International Private Limited | Not Listed | Yes, as of November | No | Not verified | Participated in India's PLI scheme for pharmaceuticals as of November 2021. |
| Steril-Gene Life Sciences Private Limited | Not Listed | Yes, as of November | No | Not verified | Participated in India's PLI scheme for pharmaceuticals as of November 2021. |
| Wockhardt Limited | Approved | Yes, as of December | Yes | Multiple | Holds multiple FDA approvals and WHO-GMP certification. |
| Granules India Limited | Approved | Yes, as of December | Yes | Multiple | Holds multiple FDA approvals and WHO-GMP certification. |
| Caplin Point Laboratories Limited | Approved | Yes, as of December | Yes | Multiple | Holds multiple FDA approvals and WHO-GMP certification. |
| Neon Laboratories Limited | Not Listed | Yes, as of December | No | Not verified | Holds WHO-GMP certification. |
| Khandelwal Laboratories Private Limited | Not Listed | Yes, as of December | No | Not verified | Holds WHO-GMP certification. |
TransData Nexus reviewed the regulatory standing of 8 leading Tamoxifen exporters from India. 3 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 3 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Tamoxifen sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as India's "Bulk Drug Capital," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical landscape is anchored by Genome Valley, a hub for R&D and biologics, and Hyderabad Pharma City, an integrated cluster under development aimed at consolidating APIs, formulations, and support services. This robust infrastructure positions Hyderabad as a pivotal player in the API sector, potentially contributing significantly to Tamoxifen production.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a prominent formulations hub, housing major pharmaceutical companies like Zydus Lifesciences and Cadila Pharmaceuticals. These companies are engaged in the manufacturing of generic drugs and formulations, indicating a strong capacity for producing finished Tamoxifen products. The region's deep chemical supply chains and proximity to ports like Mundra and Pipavav facilitate efficient export logistics.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. This region hosts numerous pharmaceutical headquarters and regulatory affairs talent, providing strategic advantages for companies aiming to export products like Tamoxifen. The proximity to major ports enhances the efficiency of international distribution channels.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi and Nalagarh in Himachal Pradesh have emerged as significant pharmaceutical hubs, initially attracting companies through tax incentives. Despite the expiration of some tax benefits, the region maintains a strong manufacturing ecosystem with a skilled workforce and established infrastructure, supporting the production of various pharmaceutical formulations.
5Sourcing Recommendations
- Diversify Supplier Base: Given that the top five exporters account for 87.8% of Tamoxifen shipments, it's advisable to diversify sourcing to mitigate risks associated with supplier concentration.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and compliance records of suppliers in Hyderabad and Ahmedabad-Vadodara clusters, as these regions are pivotal in API and formulation production.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline international distribution and reduce logistical complexities.
- Monitor Regulatory Compliance: Ensure that selected suppliers adhere to international regulatory standards, facilitating smoother market entry and reducing the risk of compliance issues.
By strategically engaging with suppliers across these key pharmaceutical clusters, companies can optimize their Tamoxifen sourcing strategies, ensuring a stable and compliant supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Tamoxifen exporters from India
EUGIA PHARMA SPECIALITIES LIMITED — Acquisition of Khandelwal's Non-Oncology Business
EUGIA PHARMA SPECIALITIES LIMITED, a wholly-owned subsidiary of Aurobindo Pharma Limited, acquired the non-oncology prescription formulations business of Khandelwal Laboratories Private Limited for ₹3.2 billion. IMPACT: This acquisition is expected to enhance EUGIA's product portfolio, potentially increasing its Tamoxifen export capacity.
Impact: This acquisition is expected to enhance EUGIA's product portfolio, potentially increasing its Tamoxifen export capacity.
EUGIA PHARMA SPECIALITIES LIMITED — US FDA Approval for Everolimus Tablets
EUGIA PHARMA SPECIALITIES LIMITED received approval from the US FDA to manufacture and market Everolimus Tablets, expanding its oncology product offerings. IMPACT: This approval may bolster EUGIA's reputation in oncology, indirectly supporting Tamoxifen exports.
Impact: This approval may bolster EUGIA's reputation in oncology, indirectly supporting Tamoxifen exports.
EUGIA PHARMA SPECIALITIES LIMITED — Completion of US FDA Inspection at Unit I
EUGIA PHARMA SPECIALITIES LIMITED announced the successful completion of a US FDA inspection at its Unit I facility, with no critical observations reported. IMPACT: The positive inspection outcome reinforces EUGIA's compliance standards, potentially boosting confidence in its Tamoxifen exports.
Impact: The positive inspection outcome reinforces EUGIA's compliance standards, potentially boosting confidence in its Tamoxifen exports.
Common Questions — Tamoxifen Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which tamoxifen supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, EUGIA PHARMA SPECIALITIES LIMITED leads with 182 recorded shipments worth $6.7M. PRATAP ORGANICS PRIVATE LIMITED (7 shipments) and GRANULES INDIA LIMITED (25 shipments) are also established high-volume exporters.
Q How many tamoxifen manufacturers are there in India?
India has 220 active tamoxifen exporters with a combined export market of $14.7M across 3,139 shipments to 104 countries. The top 5 suppliers hold 87.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for tamoxifen from India?
Average FOB unit price: $3.83 per unit, ranging from $0.01 to $2094.02. Average shipment value: $4.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 220 verified Indian exporters of Tamoxifen ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,139 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 104 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,139 Verified Shipments
220 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists